The boston ocular surface prosthesis as a novel drug delivery system for bevacizumab

Seminars in Ophthalmology

Volumn 24, Issue 3, 2009, Pages 149-155

  Lim, Mira ^a,c   Jacobs, Deborah S ^b   Rosenthal, Perry ^b   Carrasquillo, Karen G ^b  

^a MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

^b Boston Foundation for Sight   (United States)

^c Ophthalmic Education   (United States)

Author keywords

Bevacizumab; Corneal neovascularization; Scleral lens

Indexed keywords

ARTIFICIAL TEAR; BEVACIZUMAB; BRIMONIDINE; CARBAMAZEPINE; CYCLOSPORIN A; ERYTHROMYCIN; KETOROLAC TROMETAMOL; LATANOPROST; LOTEPREDNOL ETABONATE; MOXIFLOXACIN; PREDNISOLONE ACETATE; TIMOLOL MALEATE; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY;

ABSENCE OF SIDE EFFECTS; ADULT; CLINICAL ARTICLE; CONTACT LENS; CORNEA EPITHELIUM; CORNEA NEOVASCULARIZATION; DRUG DELIVERY SYSTEM; FEMALE; HUMAN; KERATITIS; KERATOPROSTHESIS; MALE; OUTCOME ASSESSMENT; PANNUS; PRIORITY JOURNAL; REVIEW; STEVENS JOHNSON SYNDROME; VISUAL ACUITY; ARTICLE; CASE REPORT; CORNEA; HYDROPHILIC CONTACT LENS; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PROSTHESES AND ORTHOSES; UNITED STATES;

ADULT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; BOSTON; CONTACT LENSES, HYDROPHILIC; CORNEA; CORNEAL NEOVASCULARIZATION; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSTHESES AND IMPLANTS; VISUAL ACUITY;

EID: 67651160632     PISSN: 08820538     EISSN: 17445205     Source Type: Journal    
DOI: 10.1080/08820530902802013     Document Type: Review

References (33)

1. Azar D. Corneal angiogenic privilege: Angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing. Trans Am Ophthalmol Soc 2006;104:264- 302.
2. Cursiefen C, Maruyama K, Liu Y, et al. Inhibition of hem- and lymphangiogenesis after normal risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest Ophthalmol Vis Sci 2004;45:2566-2673.
3. Dana RM, Streilein WJ. Loss and restoration of immune privilege in eyes with corneal neovascularization. Investigative Ophthalmology and Visual Science 1996;37(12):2485-2494.
4. Epstein RJ, Stulting RD, Hendricks RL, et al. Corneal neovascularization: Pathogenesis and inhibition. Cornea 1987;6(4):250- 257.
5. Epstein RJ, Hendricks RL, Harris DM. Photodynamic therapy for corneal neovascularization. Cornea 1991;10(5):424-432.
6. Chang JH, Gabison EE, Kato T, el al. Corneal neovascularization. Curr Opin Ophthalmol 2001;12(4):242-249
7. Cursiefen C, Chen L, Saint-Geniez M, et al. Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision. PNAS 2006;103(30):11405- 11410.
8. Azar 2006, Philipp W, Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human cornea. IOVS 2000;41:2514-2522.
9. Kvanta A, Sarman S, Fagerholm P, et al. Expression of matrix metalloproteinase-2 (MMP-2) and vascular endothelial growth factor (VEGF) in inflammation-associated corneal neovascularization. Exp Eye Res 2000;70:419-428.
10. Amano S, Rohan R, Kuroki M, et al. Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci 1998;39:18-22.
11. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2005;113:363-372.
12. Avery RL. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina 2006;26:352-354.
13. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after and intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2005;36:336-339.
14. Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 2006;26:275-278.
15. Iliev ME, Domig D, Wolf-Schnurrbursch U, et al. Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol 2006;142:1054-1056.
16. Han YS, Jung JW, Lee JS. Inhibitory effects of bevacizumab on angiogenesis and corneal neovascularization. Graefes Arch Clin Exp Ophthalmol (in press).
17. Manzano RP, Peyman GA, Khan P. Inhibition of corneal neovascularization by bevacizumab (Avastin). Br J Ophthal 2007;91(6):804-807.
18. Kim TI, Kim SW, Kim S. Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab. Cornea 2008;27(3):349-357.
19. Bock F, Onderka J, Dietrich T, et al. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. IOVS 2007;48(6):2545-2552.
20. Miltiadis P, Theodossiadis PG, Liarakos VS, et al. Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model. Am J Ophthalmol 2008;145:424-431.
21. Erdurmus M, Totan Y. Subconjunctival bevacizumab for corneal neovascularization. Graefe's Arch Clin Exp Ophthlamol 2007;245:1577-1579.
22. Carrasco, MA. Subconjunctival bevacizumab for corneal neovascularization in herpetic stromal keratitis. Cornea 2008;27(8): 743-745.
23. Doctor PP, Bhat PV, Foster SC. Subconjunctival bevacizumab for corneal neovascularization. Cornea 2008;27:992-995.
24. DiStafeno JJ, Kim T. Topical bevacizumab therapy for corneal neovascularization. Arch Ophthalmol 2007;125(6):834-836.
25. Yoeruek E, Ziemssen F, Henke-Fahle S. Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eye-drops in corneal neovascularization after chemical burn. Acta Ophthalmolgica 2008;86:322-328.
26. Bock F, Konig Y, Kruse F et al. Bevacizumab (Avastin) eye drops inhibit corneal neovascularization. Graefe's Archive for Clinical and Experimental 2008 Feb;246(2):281-284.
27. Uy HS, Chan PS, Ang RE. Topical bevacizumab and ocular surface neovascularization in patients with stevens-johnson syndrome. Cornea 2008;27(1):70-73.
28. Kim SW, Ha BJ, Kim EK, et al. The effect of topical bevacizumab on corneal neovascularization. Ophthalmology 2008;115(6):e33- e88.
29. Jacobs D. Update on scleral lenses. Curr Opinion in Ophthalmol 2008;19(4):298-301.
30. Romeo-Rangel T, Stavrou P, Cotter J, et al. Gas permeable scleral contact lens therapy in ocular surface disease. Am J Ophthalmology 2000;130(1):25-32.
31. Kim SW, Ha BJ, Kim EK, et al. The effect of topical bevacizumab on corneal neovascularization. Ophthalmology 2008;115(6):e33- e88.
32. DeStefano JJ, Kim T. Topical bevacizumab therapy for corneal neovascularization. Arch Ophthalmol 2007;125(6):834-836.
33. Hurwitz H, Saini S. Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events. Semin Oncol 2006;3(5 Suppl 10):S26-S34.